Oxaliplatin plus gemcitabine as a salvage schedule for hormone-refractory prostate adenocarcinoma

Clin Transl Oncol. 2008 Jun;10(6):372-4. doi: 10.1007/s12094-008-0214-9.

Abstract

We report a case of hormone-refractory prostate cancer (HRPC) treated with oxaliplatin plus gemcitabine in a third-line schedule after liver progression, with an excellent clinical, biochemical and radiological response and with an acceptable tolerance. Prior chemotherapy regimens included docetaxel plus estramustine and oral etoposide. To our knowledge, this is the first report that shows this approach in an HRPC patient.

Publication types

  • Case Reports

MeSH terms

  • Adenocarcinoma / drug therapy*
  • Adenocarcinoma / pathology
  • Adenocarcinoma / physiopathology
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Deoxycytidine / administration & dosage
  • Deoxycytidine / analogs & derivatives
  • Gemcitabine
  • Humans
  • Male
  • Middle Aged
  • Neoplasm Recurrence, Local / drug therapy
  • Organoplatinum Compounds / administration & dosage
  • Oxaliplatin
  • Prostate-Specific Antigen / blood
  • Prostatic Neoplasms / drug therapy*
  • Prostatic Neoplasms / pathology
  • Prostatic Neoplasms / physiopathology
  • Salvage Therapy / methods*
  • Tomography, X-Ray Computed

Substances

  • Organoplatinum Compounds
  • Oxaliplatin
  • Deoxycytidine
  • Prostate-Specific Antigen
  • Gemcitabine